Nortriptyline (Pamelor) is a tricyclic antidepressant (TCA) — the active metabolite of amitriptyline — used to treat major depression, neuropathic pain (including diabetic peripheral neuropathy and postherpetic neuralgia), and migraine prophylaxis. It works by preferentially inhibiting norepinephrine reuptake over serotonin reuptake, plus anticholinergic, antihistamine, and alpha-1 adrenergic receptor blockade. Common side effects include dry mouth, constipation, sedation, and orthostatic hypotension. It is lethal in overdose at only 10–20 times the therapeutic dose; therapeutic drug monitoring (target range 50–150 ng/mL) is recommended, and it is contraindicated in patients with recent myocardial infarction.
Nortriptyline
Uses & FDA Indications
Nortriptyline is the most clinically favored tricyclic antidepressant for non-geriatric adult use — it retains the pain and antidepressant efficacy of the TCA class with a more tolerable side effect profile than parent compounds like amitriptyline.
FDA-approved indications: major depressive disorder (MDD) in adults. Like most TCAs, it was approved before the modern evidence-based framework, and its clinical use now extends well beyond the label.
Well-established off-label uses include: neuropathic pain (diabetic peripheral neuropathy, postherpetic neuralgia — recommended in multiple pain management guidelines), migraine prophylaxis, chronic tension-type headache prevention, and smoking cessation (modest evidence). The analgesic effect on neuropathic pain occurs independently of antidepressant effect and at lower plasma concentrations — patients do not need depression to benefit.
How It Works
Nortriptyline is the secondary amine active metabolite of amitriptyline (a tertiary amine TCA). The conversion from tertiary to secondary amine reduces anticholinergic activity and sedation while preserving norepinephrine (NE) and serotonin reuptake inhibition — the proposed primary mechanism of antidepressant and analgesic efficacy.
Nortriptyline preferentially inhibits norepinephrine reuptake over serotonin reuptake. The NE reuptake inhibition is relevant to both its antidepressant activity and its efficacy in neuropathic pain via descending noradrenergic pain modulation pathways. Additional receptor activities — antihistamine (H1), anticholinergic (muscarinic), and alpha-1 adrenergic blockade — contribute to sedation, weight gain, dry mouth, and orthostatic hypotension.
Nortriptyline is one of the few antidepressants with a demonstrated curvilinear (inverted U-shaped) dose-response relationship: plasma levels below 50 ng/mL are subtherapeutic, 50-150 ng/mL is the therapeutic window, and levels above the window are associated with reduced efficacy and increased toxicity. This makes therapeutic drug monitoring (TDM) clinically useful and distinguishes nortriptyline from SSRIs where serum levels are not routinely used to guide dosing.
FDA BLACK BOX WARNING - SUICIDALITY IN YOUTH: Antidepressants increase the risk of suicidal thinking and behavior in children, adolescents, and young adults under 25. Monitor closely during initial treatment and dose changes. CRITICAL SAFETY NOTE: TCAs including nortriptyline are lethal in overdose - 10-20x the therapeutic dose can cause fatal cardiac arrhythmia. In patients with suicidal ideation, limit the quantity supplied per prescription. Nortriptyline should not be used in patients with recent myocardial infarction.
Side Effects
Common
- Dry mouth - anticholinergic (muscarinic blockade); very common; may improve with time
- Constipation - anticholinergic; can be severe
- Sedation - antihistamine effect; less than amitriptyline; often exploited for nighttime dosing in comorbid insomnia
- Weight gain - H1 antihistamine effect increases appetite
- Orthostatic hypotension - alpha-1 blockade; dizziness on standing; fall risk particularly in elderly
- Urinary retention - anticholinergic; particularly concerning in men with BPH
- Blurred vision - anticholinergic effect on ciliary muscle
- Tremor - noradrenergic effect
Serious
- QTc prolongation and cardiac conduction abnormalities - TCAs block cardiac sodium and potassium channels. PR, QRS, and QT interval prolongation can occur, particularly at supratherapeutic levels. Baseline ECG recommended in elderly and cardiac-risk patients.
- Lethal in overdose - 10-20x therapeutic levels cause fatal ventricular arrhythmia. Among the most dangerous drugs in overdose. Key consideration in patient selection and supply limits.
- Serotonin syndrome - risk with MAOIs, tramadol, and other serotonergic drugs
- Anticholinergic toxicity - in overdose: agitation, hyperthermia, urinary retention, tachycardia, delirium
Drug Interactions
| Drug / Class | Interaction | Clinical Significance |
|---|---|---|
| MAO Inhibitors | Risk of severe serotonin syndrome and hypertensive crisis. Combination is potentially fatal. 14-day washout required between TCAs and classic MAOIs. | CONTRAINDICATED — absolute |
| CYP2D6 Inhibitors (paroxetine, fluoxetine, bupropion) | CYP2D6 metabolizes nortriptyline. Potent inhibitors can increase nortriptyline plasma levels 2-5 fold, raising toxicity risk (cardiac conduction effects, anticholinergic toxicity). TDM is critical if combined. | HIGH — TDM required; nortriptyline dose reduction likely necessary |
| QT-Prolonging Drugs (antipsychotics, antiarrhythmics, fluoroquinolones, methadone) | Additive QTc prolongation with risk of torsades de pointes. | High — ECG monitoring required; avoid high-risk combinations |
| Anticholinergic Drugs (antihistamines, bladder agents, atropine) | Additive anticholinergic burden — dry mouth, constipation, urinary retention, cognitive impairment, confusion. Particular concern in elderly. | Moderate-High — assess total anticholinergic burden |
| Alcohol | Additive CNS depression — enhanced sedation; worsens underlying depression. Alcohol transiently inhibits nortriptyline metabolism. | Moderate — advise avoidance, particularly during initial treatment |
| Sympathomimetics (epinephrine, norepinephrine) | NE reuptake blockade potentiates exogenous sympathomimetics — cardiovascular effects (hypertension, arrhythmia) can be exaggerated. Relevant in anesthesia settings. | Moderate — relevant in anesthesia and emergency medicine settings |
Warnings & Contraindications
Contraindications
- Recent myocardial infarction (within the recovery phase)
- Concomitant use with MAO inhibitors
- Hypersensitivity to nortriptyline or other dibenzazepine compounds
Narrow Therapeutic Index — Therapeutic Drug Monitoring
Nortriptyline has a narrow therapeutic index with well-established plasma concentration targets (50-150 ng/mL). TDM is recommended in: elderly patients (altered metabolism), patients on CYP2D6 inhibitors (paroxetine, fluoxetine can dramatically raise levels), patients with inadequate response at expected doses, patients with signs of toxicity, and as a safety check in cardiac-risk patients. Samples should be drawn at steady state as trough levels (just before the next dose, typically after 5+ days at a stable dose).
Cardiac Precautions
Nortriptyline prolongs cardiac conduction intervals (PR, QRS, QTc) in a dose-dependent manner. Before initiating nortriptyline in elderly patients or those with pre-existing cardiac disease, an ECG should be obtained to assess baseline QTc and conduction. Nortriptyline is contraindicated in the acute post-myocardial infarction recovery period. During treatment, any new cardiac symptoms warrant ECG reassessment.
Suicide Risk and Supply Limits
TCAs including nortriptyline are among the most dangerous medications in overdose. As little as a 1-week supply can be lethal in an intentional overdose. In patients with suicidal ideation, depression, or substance use disorder, providers should prescribe in small quantities with frequent follow-up. Co-prescribing with a trusted third party or implementing additional safety measures should be considered in high-risk patients.
Beers Criteria — Elderly Patients
The American Geriatrics Society Beers Criteria lists all TCAs including nortriptyline as potentially inappropriate in adults 65 and older due to: anticholinergic effects (confusion, urinary retention, falls), orthostatic hypotension, cardiac conduction effects, and sedation. Despite being the best-tolerated TCA, nortriptyline should be used only when no safer alternatives exist in elderly patients.
Check for CYP2D6 interactions or cardiac risk combinations with nortriptyline.
Check Drug Interactions →Frequently Asked Questions
Is nortriptyline safer than amitriptyline?
Yes — nortriptyline is generally considered the better-tolerated TCA compared to amitriptyline, and is the preferred TCA for most clinical purposes. Nortriptyline is the active demethylated metabolite of amitriptyline. It has less anticholinergic activity (less dry mouth, constipation, urinary retention, cognitive effects), less sedation, and less orthostatic hypotension. Nortriptyline also has an established therapeutic drug monitoring range (50-150 ng/mL) and a well-characterized therapeutic window. Both drugs share the same cardiac risks and lethality in overdose, so careful prescribing and supply limits in high-risk patients apply equally.
What is nortriptyline used for besides depression?
Nortriptyline has several well-established non-psychiatric uses. For neuropathic pain — including diabetic peripheral neuropathy and postherpetic neuralgia — TCAs including nortriptyline are recommended as first- or second-line agents in multiple guidelines. The analgesic effect is independent of the antidepressant effect and occurs at lower plasma levels. For migraine prevention, nortriptyline is among the established preventive agents alongside beta-blockers, topiramate, and valproate. It is also used off-label for smoking cessation and chronic pain syndromes including fibromyalgia and tension-type headache.
What level should nortriptyline be?
The therapeutic plasma concentration range for nortriptyline is 50-150 ng/mL. This is one of the best-characterized therapeutic windows among antidepressants — nortriptyline shows a curvilinear dose-response relationship where both subtherapeutic and supratherapeutic levels are associated with reduced efficacy. Levels above 150-200 ng/mL carry increased cardiac risk. Therapeutic drug monitoring is particularly valuable in elderly patients, those on CYP2D6 inhibitors (paroxetine, fluoxetine dramatically raise levels), and patients who fail to respond at expected doses. Blood should be drawn at steady state as a trough level — just before the next dose.